SOURCE: SciClone Pharmaceuticals, Inc.

July 11, 2006 06:30 ET

SciClone to Report Second Quarter 2006 Results on August 1, 2006

SAN MATEO, CA -- (MARKET WIRE) -- July 11, 2006 --SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report second quarter 2006 results and host a conference call on Tuesday, August 1, 2006.

The conference call will contain forward-looking statements. Financial and statistical information to be discussed on the call will be posted on the Investor Relations section of SciClone's web site at prior to the commencement of the conference call.

DATE:           Tuesday, August 1, 2006

TIME:           11:30 a.m. ET (8:30 a.m. PT)

WEBCAST:        Live call and replay accessible at

LIVE CALL:      888-202-2422 (U.S./Canada)
                913-981-5592 (international)

REPLAY:         888-203-1112 (U.S./Canada)
                719-457-0820 (international)
                Passcode: 7044430
                (Replay available from 2:30 p.m. ET on August 1, 2006
                through 12:00 a.m. ET on August 15, 2006)
About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN is currently being evaluated in late-stage clinical trials for the treatment of malignant melanoma and hepatitis C. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. SciClone's strategy is to leverage its advantage in China by in-licensing or acquiring the marketing rights to other products to market in this rapidly growing pharmaceutical market. SciClone's other drug development candidate is SCV-07, currently in early clinical development in the U.S. for the treatment of viral and other infectious diseases. For more information about SciClone, visit

Contact Information

  • Corporate information contact:
    Becky Horner
    Investor Relations
    SciClone Pharmaceuticals, Inc.